BSX vs. DXCM, RMD, WST, BMY, CI, REGN, VRTX, MDT, GSK, and HCA
Should you be buying Boston Scientific stock or one of its competitors? The main competitors of Boston Scientific include DexCom (DXCM), ResMed (RMD), West Pharmaceutical Services (WST), Bristol-Myers Squibb (BMY), The Cigna Group (CI), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Medtronic (MDT), GSK (GSK), and HCA Healthcare (HCA). These companies are all part of the "medical" sector.
DexCom (NASDAQ:DXCM) and Boston Scientific (NYSE:BSX) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, community ranking, profitability, risk, media sentiment, earnings and valuation.
97.8% of DexCom shares are held by institutional investors. Comparatively, 89.1% of Boston Scientific shares are held by institutional investors. 0.4% of DexCom shares are held by insiders. Comparatively, 0.5% of Boston Scientific shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
DexCom has a net margin of 16.82% compared to DexCom's net margin of 12.06%. Boston Scientific's return on equity of 31.01% beat DexCom's return on equity.
Boston Scientific received 48 more outperform votes than DexCom when rated by MarketBeat users. However, 71.98% of users gave DexCom an outperform vote while only 69.31% of users gave Boston Scientific an outperform vote.
DexCom has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500. Comparatively, Boston Scientific has a beta of 0.78, meaning that its stock price is 22% less volatile than the S&P 500.
DexCom presently has a consensus price target of $141.67, indicating a potential upside of 12.60%. Boston Scientific has a consensus price target of $75.09, indicating a potential upside of 4.12%. Given Boston Scientific's higher probable upside, analysts clearly believe DexCom is more favorable than Boston Scientific.
Boston Scientific has higher revenue and earnings than DexCom. Boston Scientific is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.
In the previous week, Boston Scientific had 43 more articles in the media than DexCom. MarketBeat recorded 78 mentions for Boston Scientific and 35 mentions for DexCom. Boston Scientific's average media sentiment score of 0.64 beat DexCom's score of 0.55 indicating that DexCom is being referred to more favorably in the media.
Summary
DexCom beats Boston Scientific on 11 of the 18 factors compared between the two stocks.
Get Boston Scientific News Delivered to You Automatically
Sign up to receive the latest news and ratings for BSX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BSX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Boston Scientific Competitors List
Related Companies and Tools
